These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

570 related articles for article (PubMed ID: 29566416)

  • 1. Beyond Stroke Prevention in Atrial Fibrillation: Exploring Further Unmet Needs with Rivaroxaban.
    Gibson CM; Hankey GJ; Nafee T; Welsh RC
    Thromb Haemost; 2018 May; 118(S 01):S34-S44. PubMed ID: 29566416
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Spotlight on unmet needs in stroke prevention: The PIONEER AF-PCI, NAVIGATE ESUS and GALILEO trials.
    Hemmrich M; Peterson ED; Thomitzek K; Weitz JI
    Thromb Haemost; 2016 Sep; 116(Suppl. 2):S33-S40. PubMed ID: 27623683
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of Procedure and Coronary Lesion Characteristics on Clinical Outcomes Among Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention: Insights From the PIONEER AF-PCI Trial.
    Kerneis M; Gibson CM; Chi G; Mehran R; AlKhalfan F; Talib U; Pahlavani S; Mir M; Bode C; Halperin JL; Nafee T; Peterson ED; Verheugt FWA; Wildgoose P; van Eickels M; Lip GYH; Fox KAA; Cohen M
    JACC Cardiovasc Interv; 2018 Apr; 11(7):626-634. PubMed ID: 29550085
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of International Normalized Ratio Stability and Bleeding Outcomes Among Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention.
    Kerneis M; Yee MK; Mehran R; Nafee T; Bode C; Halperin JL; Peterson ED; Verheugt FWA; Wildgoose P; van Eickels M; Lip GYH; Cohen M; Fox KAA; Gibson CM
    Circ Cardiovasc Interv; 2019 Feb; 12(2):e007124. PubMed ID: 30704287
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of Dual Antiplatelet Therapy and Patient Outcomes in Those Undergoing Percutaneous Coronary Intervention: The ROCKET AF Trial.
    Sherwood MW; Cyr DD; Jones WS; Becker RC; Berkowitz SD; Washam JB; Breithardt G; Fox KA; Halperin JL; Hankey GJ; Singer DE; Piccini JP; Nessel CC; Mahaffey KW; Patel MR
    JACC Cardiovasc Interv; 2016 Aug; 9(16):1694-702. PubMed ID: 27539689
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antithrombotic therapy in patients with non-valvular atrial fibrillation undergoing percutaneous coronary intervention: should we change our practice after the PIONEER AF-PCI and RE-DUAL PCI trials?
    Duerschmied D; Brachmann J; Darius H; Frey N; Katus HA; Rottbauer W; Schäfer A; Thiele H; Bode C; Zeymer U
    Clin Res Cardiol; 2018 Jul; 107(7):533-538. PubMed ID: 29679144
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of rivaroxaban in atrial fibrillation and acute coronary syndromes.
    Reddy P; Giugliano RP
    J Cardiovasc Pharmacol Ther; 2014 Nov; 19(6):526-32. PubMed ID: 24659084
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Understanding the Value of Real-World Evidence: Focus on Stroke Prevention in Atrial Fibrillation with Rivaroxaban.
    Camm AJ; Coleman CI; Larsen TB; Nielsen PB; Tamayo CS
    Thromb Haemost; 2018 May; 118(S 01):S45-S60. PubMed ID: 29566414
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of rivaroxaban in the management of atrial fibrillation: insights from clinical practice.
    Vimalesvaran K; Dockrill SJ; Gorog DA
    Vasc Health Risk Manag; 2018; 14():13-21. PubMed ID: 29391805
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rivaroxaban in the Prevention of Stroke and Systemic Embolism in Patients with Non-Valvular Atrial Fibrillation: Clinical Implications of the ROCKET AF Trial and Its Subanalyses.
    Spencer RJ; Amerena JV
    Am J Cardiovasc Drugs; 2015 Dec; 15(6):395-401. PubMed ID: 26062914
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-world vs. randomized trial outcomes in similar populations of rivaroxaban-treated patients with non-valvular atrial fibrillation in ROCKET AF and XANTUS.
    Camm AJ; Amarenco P; Haas S; Hess S; Kirchhof P; Lambelet M; Bach M; Turpie AGG
    Europace; 2019 Mar; 21(3):421-427. PubMed ID: 30052894
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trial design: Rivaroxaban for the prevention of major cardiovascular events after transcatheter aortic valve replacement: Rationale and design of the GALILEO study.
    Windecker S; Tijssen J; Giustino G; Guimarães AH; Mehran R; Valgimigli M; Vranckx P; Welsh RC; Baber U; van Es GA; Wildgoose P; Volkl AA; Zazula A; Thomitzek K; Hemmrich M; Dangas GD
    Am Heart J; 2017 Feb; 184():81-87. PubMed ID: 27892890
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An open-label, randomized, controlled, multicenter study exploring two treatment strategies of rivaroxaban and a dose-adjusted oral vitamin K antagonist treatment strategy in subjects with atrial fibrillation who undergo percutaneous coronary intervention (PIONEER AF-PCI).
    Gibson CM; Mehran R; Bode C; Halperin J; Verheugt F; Wildgoose P; van Eickels M; Lip GY; Cohen M; Husted S; Peterson E; Fox K
    Am Heart J; 2015 Apr; 169(4):472-8.e5. PubMed ID: 25819853
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Apixaban versus Antiplatelet drugs or no antithrombotic drugs after anticoagulation-associated intraCerebral HaEmorrhage in patients with Atrial Fibrillation (APACHE-AF): study protocol for a randomised controlled trial.
    van Nieuwenhuizen KM; van der Worp HB; Algra A; Kappelle LJ; Rinkel GJ; van Gelder IC; Schutgens RE; Klijn CJ;
    Trials; 2015 Sep; 16():393. PubMed ID: 26340977
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcomes of discontinuing rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: analysis from the ROCKET AF trial (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation).
    Patel MR; Hellkamp AS; Lokhnygina Y; Piccini JP; Zhang Z; Mohanty S; Singer DE; Hacke W; Breithardt G; Halperin JL; Hankey GJ; Becker RC; Nessel CC; Berkowitz SD; Califf RM; Fox KA; Mahaffey KW
    J Am Coll Cardiol; 2013 Feb; 61(6):651-8. PubMed ID: 23391196
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF).
    Halperin JL; Hankey GJ; Wojdyla DM; Piccini JP; Lokhnygina Y; Patel MR; Breithardt G; Singer DE; Becker RC; Hacke W; Paolini JF; Nessel CC; Mahaffey KW; Califf RM; Fox KA;
    Circulation; 2014 Jul; 130(2):138-46. PubMed ID: 24895454
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The INVICTUS rheumatic heart disease research program: Rationale, design and baseline characteristics of a randomized trial of rivaroxaban compared to vitamin K antagonists in rheumatic valvular disease and atrial fibrillation.
    Karthikeyan G; Connolly SJ; Ntsekhe M; Benz A; Rangarajan S; Lewis G; Yun Y; Sharma SK; Maklady F; Elghamrawy AE; Kazmi K; Cabral TTJ; Dayi H; Changsheng M; Gitura BM; Avezum A; Zuhlke L; Lwabi P; Haileamlak A; Ogah O; Chillo P; Paniagua M; ElSayed A; Dans A; Gondwe-Chunda L; Molefe-Baikai OJ; Gonzalez-Hermosillo JA; Hakim J; Damasceno A; Kamanzi ER; Musuku J; Davletov K; Connolly K; Mayosi BM; Yusuf S;
    Am Heart J; 2020 Jul; 225():69-77. PubMed ID: 32474206
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of concomitant aspirin in patients with atrial fibrillation: Findings from the ROCKET AF trial.
    Shah R; Hellkamp A; Lokhnygina Y; Becker RC; Berkowitz SD; Breithardt G; Hacke W; Halperin JL; Hankey GJ; Fox KA; Nessel CC; Mahaffey KW; Piccini JP; Singer DE; Patel MR;
    Am Heart J; 2016 Sep; 179():77-86. PubMed ID: 27595682
    [TBL] [Abstract][Full Text] [Related]  

  • 19. XANTUS: rationale and design of a noninterventional study of rivaroxaban for the prevention of stroke in patients with atrial fibrillation.
    Camm AJ; Amarenco P; Haas S; Hess S; Kirchhof P; van Eickels M; Turpie AG
    Vasc Health Risk Manag; 2014; 10():425-34. PubMed ID: 25083135
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduced Leaflet Motion after Transcatheter Aortic-Valve Replacement.
    De Backer O; Dangas GD; Jilaihawi H; Leipsic JA; Terkelsen CJ; Makkar R; Kini AS; Veien KT; Abdel-Wahab M; Kim WK; Balan P; Van Mieghem N; Mathiassen ON; Jeger RV; Arnold M; Mehran R; Guimarães AHC; Nørgaard BL; Kofoed KF; Blanke P; Windecker S; Søndergaard L;
    N Engl J Med; 2020 Jan; 382(2):130-139. PubMed ID: 31733182
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.